Direct Healthcare Professional Communication (DHPC) on Xagrid® (anagrelide hydrochloride): Risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation
2022.02.22
Active substance: anagrelide hydrochloride
Shire Pharmaceuticals Ireland Limited (a subsidiary of Takeda Pharmaceuticals Company Limited) in agreement with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devises (BfArM) would like to inform you that there is an increased risk of thrombotic complications, including cerebral infarction, upon abrupt anagrelide discontinuation. Abrupt treatment discontinuation should be avoided due to the risk of sudden increase in platelet counts and potentially fatal thrombotic complications, such as cerebral infarction.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN